



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

002

Reagent: rVV/ROD

Catalog Number: 770

Lot Number:

Provided: 1 vial cell-free virus, 2×10^9 pfu/ml at 72 hours.

Cloning Vector: Vaccinia virus, strain IHDJ. Infects a wide range of mammalian cells.

Description: Expresses the *env* gene of HIV-2ROD. The 3181 bp *Ava*1-*Asp*718 fragment excised from plasmid pS2E2, encompassing 88 nucleotides 5' to the *env* AUG, was ligated into the *Sma*1 site of the vaccinia virus recombination vector.² The *env* gene was inserted into recombination plasmid pSC11 (Dr. Bernard Moss, NIAID), followed by homologous recombination into the TK gene of vaccinia. *Env*,/i> expression is under control of the vaccinia p7.5 early/late promoter; *env* is co-expressed with the *lacZ* gene under control of p11 vaccinia promoter³.

Special Characteristics: HIV-2/ROD is cytopathic *in vitro*². It was initially provided by Dr. L. Montagnier, Institute Pasteur, Paris. rVV/ROD expresses high levels of HIV-2 envelope protein that is processed and transported to the cell surface.

Recommended Storage: -70degreeC.

Contributor: Dr. Mark J. Mulligan, Departments of Medicine and Microbiology, University of Alabama, Birmingham, AL.

References: 1. Mulligan MJ, Kumar P, Hui H, Owens R, Ritter D, Hahn B. The env protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation. *AIDS Res Hum Retroviruses* **6**:707-720, 1990. 2. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. *Nature* **326**:662-669, 1987. 3. Mulligan MJ, Ritter GD, Chaikin MA, Yamschikov GV, Kumar P, Hahn BH, Sweet RW, Compans RW. Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex. *Virology* **187**:233-241, 1992. 4. Mulligan MJ, Yamschikov GV, Ritter GD, Chaikin MA, Hahn BH, Sweet RW, Compans RW

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Yamsnikov GV, Ritter GD Jr, Gao F, Jin MJ, Nail CD, Spies CP, Mann BH, Compans RW. Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types. *J Virol* **66**:3971-3975, 1992.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: rVV/ROD from Dr. Mark J. Mulligan." Also include the references cited above in any publications.

The US Government has submitted a patent application on the parent plasmid pSC11.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Sally Hu at the NIH Office of Technology Transfer, Email: hus@mail.nih.gov, Phone: 301-435-5606, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated:

June 24, 2013

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.